Compounds > adenallene
Page last updated: 2024-10-15

adenallene

Description

adenallene: structure given in first source; inhibits replication and cytopathic effects of HIV in vitro [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID135436544
CHEMBL ID313478
SCHEMBL ID4480283
MeSH IDM0159494

Synonyms (28)

Synonym
CHEMBL313478
mls000757229 ,
n(sup9)-(4-hydroxy-1,2-butadien-1-yl)adenine
nsc-622175
(r)-(-)-9-(4-hydroxy-1,2-butadien-1-yl)adenine
NCI60_006455
r-(-)-adenallene
s-(+)-adenallene
(r)-(-)-n^9-(4-hydroxy-1,2-butadien-1-yl)adenine
(s)-(+)-n^9-(4-hydroxy-1,2-butadien-1-yl)adenine
4-(6-aminopurin-9-yl)buta-2,3-dien-1-ol
114987-18-7
adenallene
nsc622175
2,3-butadien-1-ol, 4-(6-amino-9h-purin-9-yl)-, (+/-)-
smr000529049
4-(6-amino-9h-purin-9-yl)buta-2,3-dien-1-ol
NCGC00246850-01
HMS2885E04
2,3-butadien-1-ol, 4-(6-amino-9h-purin-9-yl)-, (+-)-
9-(4'-hydroxy-1',2'-butadienyl)adenine
SCHEMBL4480283
9-(4-hydroxyl-1,2-butadienyl)adenine
DTXSID20150910
[9-(4-hydroxybut-2-enylidene)purin-9-ium-6-yl]azanide
STARBLD0004547
2,3-butadien-1-ol, 4-(6-amino-9h-purin-9-yl)-
AKOS040745486

Dosage Studied

ExcerptReference
"1-10 microM but the dose-response relationship was poor."( Phosphodiester amidates of allenic nucleoside analogues: anti-HIV activity and possible mechanism of action.
Maeda, Y; Mitsuya, H; Winter, H; Zemlicka, J, 1996)
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Protein Targets (11)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Chain A, Putative fructose-1,6-bisphosphate aldolaseGiardia intestinalisPotency8.91250.140911.194039.8107AID2451
Chain A, 2-oxoglutarate OxygenaseHomo sapiens (human)Potency25.11890.177814.390939.8107AID2147
TDP1 proteinHomo sapiens (human)Potency3.35120.000811.382244.6684AID686978; AID686979
thioredoxin glutathione reductaseSchistosoma mansoniPotency79.43280.100022.9075100.0000AID485364
P53Homo sapiens (human)Potency35.48130.07319.685831.6228AID504706
chromobox protein homolog 1Homo sapiens (human)Potency100.00000.006026.168889.1251AID540317
importin subunit beta-1 isoform 1Homo sapiens (human)Potency4.61095.804836.130665.1308AID540253
snurportin-1Homo sapiens (human)Potency4.61095.804836.130665.1308AID540253
GTP-binding nuclear protein Ran isoform 1Homo sapiens (human)Potency4.61095.804816.996225.9290AID540253
lamin isoform A-delta10Homo sapiens (human)Potency5.62340.891312.067628.1838AID1487
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Other Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (5)

Processvia Protein(s)Taxonomy
adenosine catabolic processAdenosine deaminase Bos taurus (cattle)
cell adhesionAdenosine deaminase Bos taurus (cattle)
nucleotide metabolic processAdenosine deaminase Bos taurus (cattle)
purine ribonucleoside monophosphate biosynthetic processAdenosine deaminase Bos taurus (cattle)
inosine biosynthetic processAdenosine deaminase Bos taurus (cattle)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (4)

Processvia Protein(s)Taxonomy
adenosine deaminase activityAdenosine deaminase Bos taurus (cattle)
protein bindingAdenosine deaminase Bos taurus (cattle)
zinc ion bindingAdenosine deaminase Bos taurus (cattle)
2'-deoxyadenosine deaminase activityAdenosine deaminase Bos taurus (cattle)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (3)

Processvia Protein(s)Taxonomy
lysosomeAdenosine deaminase Bos taurus (cattle)
cytoplasmic vesicle lumenAdenosine deaminase Bos taurus (cattle)
anchoring junctionAdenosine deaminase Bos taurus (cattle)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (40)

Assay IDTitleYearJournalArticle
AID213150Inhibition of incorporation of labeled precursor into macromolecules of noninfected SC-1 cells with the compound at a concentration 100 uM determined against thymidine1991Journal of medicinal chemistry, Jan, Volume: 34, Issue:1
Unsaturated and carbocyclic nucleoside analogues: synthesis, antitumor, and antiviral activity.
AID45174Cytotoxic concentration required to inhibit the replication of HIV-1 in CEM-SS human T4 lymphoblastoid cell lines2002Bioorganic & medicinal chemistry letters, Jan-21, Volume: 12, Issue:2
Increase of the adenallene anti-HIV activity in cell culture using its bis(tBuSATE) phosphotriester derivative.
AID33841Vmax by adenosine deaminase1992Journal of medicinal chemistry, Oct-30, Volume: 35, Issue:22
(R)-(-)- and (S)-(+)-adenallene: synthesis, absolute configuration, enantioselectivity of antiretroviral effect, and enzymic deamination.
AID82111Compound was tested for inhibition of HIV-11992Journal of medicinal chemistry, Oct-30, Volume: 35, Issue:22
(R)-(-)- and (S)-(+)-adenallene: synthesis, absolute configuration, enantioselectivity of antiretroviral effect, and enzymic deamination.
AID142336Inhibitory activity against murine leukemia L1210 cells1991Journal of medicinal chemistry, Jan, Volume: 34, Issue:1
Unsaturated and carbocyclic nucleoside analogues: synthesis, antitumor, and antiviral activity.
AID32071Compound was evaluated for the inhibition of infectivity and cytopathic effect of HIV-1 in ATH8 cells1996Journal of medicinal chemistry, Aug-16, Volume: 39, Issue:17
Phosphodiester amidates of allenic nucleoside analogues: anti-HIV activity and possible mechanism of action.
AID213291Inhibition of incorporation of labeled precursor into macromolecules of noninfected SC-1 cells with the compound at a concentration 300 uM determined against thymidine1991Journal of medicinal chemistry, Jan, Volume: 34, Issue:1
Unsaturated and carbocyclic nucleoside analogues: synthesis, antitumor, and antiviral activity.
AID215496Inhibition of incorporation of labeled precursor into macromolecules of noninfected SC-1 cells with the compound at a concentration 100 uM determined against uridine.1991Journal of medicinal chemistry, Jan, Volume: 34, Issue:1
Unsaturated and carbocyclic nucleoside analogues: synthesis, antitumor, and antiviral activity.
AID90940Antiviral activity against HCMV was determined; No inhibition1990Journal of medicinal chemistry, Sep, Volume: 33, Issue:9
Synthesis of new (+-)-3,5-dihydroxypentyl nucleoside analogues from 1-amino-5-(benzyloxy)pentan-3-ol and their antiviral evaluation.
AID235487Selectivity index is the ratio of IC50 to EC50 of F-MuLV.1991Journal of medicinal chemistry, Jan, Volume: 34, Issue:1
Unsaturated and carbocyclic nucleoside analogues: synthesis, antitumor, and antiviral activity.
AID106900Effective concentration required to inhibit the replication of HIV-1 in MT-2 human T4 lymphoblastoid cell lines2002Bioorganic & medicinal chemistry letters, Jan-21, Volume: 12, Issue:2
Increase of the adenallene anti-HIV activity in cell culture using its bis(tBuSATE) phosphotriester derivative.
AID45549Effective concentration required to inhibit the replication of HIV-1 in CEMSS human T4 lymphoblastoid cell lines2002Bioorganic & medicinal chemistry letters, Jan-21, Volume: 12, Issue:2
Increase of the adenallene anti-HIV activity in cell culture using its bis(tBuSATE) phosphotriester derivative.
AID101201Inhibition of incorporation of labeled precursor into macromolecules of noninfected SC-1 cells with the compound at a concentration 300 uM determined against leucine.1991Journal of medicinal chemistry, Jan, Volume: 34, Issue:1
Unsaturated and carbocyclic nucleoside analogues: synthesis, antitumor, and antiviral activity.
AID71777Concentration that reduces Friend murine leukemia virus titer by 50%1991Journal of medicinal chemistry, Jan, Volume: 34, Issue:1
Unsaturated and carbocyclic nucleoside analogues: synthesis, antitumor, and antiviral activity.
AID101200Inhibition of incorporation of labeled precursor into macromolecules of noninfected SC-1 cells with the compound at a concentration 100 uM determined against leucine.1991Journal of medicinal chemistry, Jan, Volume: 34, Issue:1
Unsaturated and carbocyclic nucleoside analogues: synthesis, antitumor, and antiviral activity.
AID32070Compound was evaluated for the inhibition of replication and cytopathic effect of HIV-1 in ATH8 cells1996Journal of medicinal chemistry, Aug-16, Volume: 39, Issue:17
Phosphodiester amidates of allenic nucleoside analogues: anti-HIV activity and possible mechanism of action.
AID215497Inhibition of incorporation of labeled precursor into macromolecules of noninfected SC-1 cells with the compound at a concentration 300 uM determined against uridine.1991Journal of medicinal chemistry, Jan, Volume: 34, Issue:1
Unsaturated and carbocyclic nucleoside analogues: synthesis, antitumor, and antiviral activity.
AID33819Km by adenosine deaminase1992Journal of medicinal chemistry, Oct-30, Volume: 35, Issue:22
(R)-(-)- and (S)-(+)-adenallene: synthesis, absolute configuration, enantioselectivity of antiretroviral effect, and enzymic deamination.
AID106885Cytotoxic concentration required to inhibit the replication of HIV-1 in MT-2 human T4 lymphoblastoid cell lines2002Bioorganic & medicinal chemistry letters, Jan-21, Volume: 12, Issue:2
Increase of the adenallene anti-HIV activity in cell culture using its bis(tBuSATE) phosphotriester derivative.
AID235800Selectivity index which is the ratio of IC50 to EC50 of R-MuLV.1991Journal of medicinal chemistry, Jan, Volume: 34, Issue:1
Unsaturated and carbocyclic nucleoside analogues: synthesis, antitumor, and antiviral activity.
AID142441Cytotoxicity was evaluated1991Journal of medicinal chemistry, Jan, Volume: 34, Issue:1
Unsaturated and carbocyclic nucleoside analogues: synthesis, antitumor, and antiviral activity.
AID197658Concentration that reduces Rauscher murine leukemia virus titer by 50%1991Journal of medicinal chemistry, Jan, Volume: 34, Issue:1
Unsaturated and carbocyclic nucleoside analogues: synthesis, antitumor, and antiviral activity.
AID100775Cytotoxicity was evaluated against L1210 leukemia cell line at 1000 ug/disk.1991Journal of medicinal chemistry, Jan, Volume: 34, Issue:1
Unsaturated and carbocyclic nucleoside analogues: synthesis, antitumor, and antiviral activity.
AID96631Compound was evaluated for the clonogenic assay with murine leukemia L1210 cells1996Journal of medicinal chemistry, Aug-16, Volume: 39, Issue:17
Phosphodiester amidates of allenic nucleoside analogues: anti-HIV activity and possible mechanism of action.
AID105163Effective concentration required to inhibit the replication of HIV-1 in MT-4 human T4 lymphoblastoid cell lines2002Bioorganic & medicinal chemistry letters, Jan-21, Volume: 12, Issue:2
Increase of the adenallene anti-HIV activity in cell culture using its bis(tBuSATE) phosphotriester derivative.
AID104786Cytotoxic concentration required to inhibit the replication of HIV-1 in MT-4 human T4 lymphoblastoid cell lines2002Bioorganic & medicinal chemistry letters, Jan-21, Volume: 12, Issue:2
Increase of the adenallene anti-HIV activity in cell culture using its bis(tBuSATE) phosphotriester derivative.
AID82116Antiviral activity against HIV-1 was determined; No inhibition1990Journal of medicinal chemistry, Sep, Volume: 33, Issue:9
Synthesis of new (+-)-3,5-dihydroxypentyl nucleoside analogues from 1-amino-5-(benzyloxy)pentan-3-ol and their antiviral evaluation.
AID156088Cytotoxicity was evaluated against PO3 cell line at 500 ug/disk.1991Journal of medicinal chemistry, Jan, Volume: 34, Issue:1
Unsaturated and carbocyclic nucleoside analogues: synthesis, antitumor, and antiviral activity.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID651635Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression
AID504810Antagonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID504812Inverse Agonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (14)

TimeframeStudies, This Drug (%)All Drugs %
pre-19902 (14.29)18.7374
1990's6 (42.86)18.2507
2000's2 (14.29)29.6817
2010's3 (21.43)24.3611
2020's1 (7.14)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other14 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
SubstanceRelationship StrengthStudiesTrialsClassesRoles
adenine
[no description available]		3.23606-aminopurines;
purine nucleobase		Daphnia magna metabolite;
Escherichia coli metabolite;
human metabolite;
mouse metabolite;
Saccharomyces cerevisiae metabolite
cytosine
[no description available]		2.6730aminopyrimidine;
pyrimidine nucleobase;
pyrimidone		Escherichia coli metabolite;
human metabolite;
mouse metabolite;
Saccharomyces cerevisiae metabolite
thymine
[no description available]		1.9810pyrimidine nucleobase;
pyrimidone		Escherichia coli metabolite;
human metabolite;
mouse metabolite
9-(2-hydroxy-3-nonyl)adenine
9-(2-hydroxy-3-nonyl)adenine: specific inhibitor of adenosine deaminase		1.9810
foscarnet
Foscarnet: An antiviral agent used in the treatment of cytomegalovirus retinitis. Foscarnet also shows activity against human herpesviruses and HIV.. phosphonoformic acid : Phosphoric acid in which one of the hydroxy groups is replaced by a carboxylic acid group. It is used as the trisodium salt as an antiviral agent in the treatment of cytomegalovirus retinitis (CMV retinitis, an inflamation of the retina that can lead to blindness) and as an alternative to ganciclovir for AIDS patients who require concurrent antiretroviral therapy but are unable to tolerate ganciclovir due to haematological toxicity.		1.9710carboxylic acid;
one-carbon compound;
phosphonic acids		antiviral drug;
geroprotector;
HIV-1 reverse transcriptase inhibitor;
sodium-dependent Pi-transporter inhibitor
cytarabine
[no description available]		1.9710beta-D-arabinoside;
monosaccharide derivative;
pyrimidine nucleoside		antimetabolite;
antineoplastic agent;
antiviral agent;
immunosuppressive agent
dideoxyadenosine
Dideoxyadenosine: A dideoxynucleoside compound in which the 3'-hydroxy group on the sugar moiety has been replaced by a hydrogen. This modification prevents the formation of phosphodiester linkages which are needed for the completion of nucleic acid chains. The compound is an inhibitor of HIV replication, acting as a chain-terminator of viral DNA by binding to reverse transcriptase. Its principal side effect is nephrotoxicity. In vivo, dideoxyadenosine is rapidly metabolized to DIDANOSINE (ddI) by enzymatic deamination; ddI is then converted to dideoxyinosine monophosphate and ultimately to dideoxyadenosine triphosphate, the putative active metabolite.		1.9710adenosines;
purine 2',3'-dideoxyribonucleoside		EC 3.5.4.4 (adenosine deaminase) inhibitor;
EC 4.6.1.1 (adenylate cyclase) inhibitor
zalcitabine
Zalcitabine: A dideoxynucleoside compound in which the 3'-hydroxy group on the sugar moiety has been replaced by a hydrogen. This modification prevents the formation of phosphodiester linkages which are needed for the completion of nucleic acid chains. The compound is a potent inhibitor of HIV replication at low concentrations, acting as a chain-terminator of viral DNA by binding to reverse transcriptase. Its principal toxic side effect is axonal degeneration resulting in peripheral neuropathy.. zalcitabine : A pyrimidine 2',3'-dideoxyribonucleoside compound having cytosine as the nucleobase.		1.9710pyrimidine 2',3'-dideoxyribonucleosideantimetabolite;
antiviral drug;
HIV-1 reverse transcriptase inhibitor
zidovudine
Zidovudine: A dideoxynucleoside compound in which the 3'-hydroxy group on the sugar moiety has been replaced by an azido group. This modification prevents the formation of phosphodiester linkages which are needed for the completion of nucleic acid chains. The compound is a potent inhibitor of HIV replication, acting as a chain-terminator of viral DNA during reverse transcription. It improves immunologic function, partially reverses the HIV-induced neurological dysfunction, and improves certain other clinical abnormalities associated with AIDS. Its principal toxic effect is dose-dependent suppression of bone marrow, resulting in anemia and leukopenia.. zidovudine : A pyrimidine 2',3'-dideoxyribonucleoside compound having a 3'-azido substituent and thymine as the nucleobase.		1.9710azide;
pyrimidine 2',3'-dideoxyribonucleoside		antimetabolite;
antiviral drug;
HIV-1 reverse transcriptase inhibitor
ribavirin
Rebetron: Rebetron is tradename		1.97101-ribosyltriazole;
aromatic amide;
monocarboxylic acid amide;
primary carboxamide		anticoronaviral agent;
antiinfective agent;
antimetabolite;
antiviral agent;
EC 2.7.7.49 (RNA-directed DNA polymerase) inhibitor
adefovir
adefovir: inhibitor of African swine fever virus. adefovir(1-) : A organophosphonate oxoanion obtained by removal of a proton from the phosphonate group of adefovir, a nucleoside reverse transcriptase inhibitor. It is the major microspecies at pH 7.3 (according to Marvin v 6.2.0.).. adefovir : A member of the class of phosphonic acids that is methylphosphonic acid in which one of the methyl hydrogens has been replaced by a 2-(6-amino-9H-purin-9-yl)ethoxy group. An inhibitor of HIV-1 reverse transcriptase, the bis(t-butoxycarbonyloxymethyl) ester (dipivoxil ester) prodrug is used to treat chronic hepatitis B viral infection.		1.97106-aminopurines;
ether;
phosphonic acids		antiviral drug;
DNA synthesis inhibitor;
drug metabolite;
HIV-1 reverse transcriptase inhibitor;
nephrotoxic agent
adenosine
quinquefolan B: isolated from roots of Panax quinquefolium L.; RN not in Chemline 10/87; RN from Toxlit		1.9810adenosines;
purines D-ribonucleoside		analgesic;
anti-arrhythmia drug;
fundamental metabolite;
human metabolite;
vasodilator agent
9-(s)-(3-hydroxy-2-(phosphonomethoxy)propyl)adenine
[no description available]		1.9710
neplanocin a
neplanocin A: neplanocins are antitumor antibiotics & carbocyclic analogs of purine nucleosides from Ampullarilla regularis A11079; see also neplanocin B, neplanocin C, neplanocin D & neplanocin F; structure in first source; a potent inhibitor of S-adenosylhomocysteine hydrolase		1.9710
9-(2,3-dihydroxypropyl)adenine, (s)-isomer
[no description available]		1.9710
acyclovir
Acyclovir: A GUANOSINE analog that acts as an antimetabolite. Viruses are especially susceptible. Used especially against herpes.. acyclovir : An oxopurine that is guanine substituted by a (2-hydroxyethoxy)methyl substituent at position 9. Used in the treatment of viral infections.		7.38202-aminopurines;
oxopurine		antimetabolite;
antiviral drug
ganciclovir
[no description available]		1.97102-aminopurines;
oxopurine		antiinfective agent;
antiviral drug
penciclovir
penciclovir : A member of the class of 2-aminopurines that is guanine in which the hydrogen at position 9 is substituted by a 4-hydroxy-3-(hydroxymethyl)but-1-yl group. An antiviral drug, it is administered topically for treatment of herpes labialis. A prodrug, famciclovir, is used for oral administration.		1.97102-aminopurines;
propane-1,3-diols		antiviral drug
buciclovir
buciclovir: structure given in first source		1.9710
9-(4-hydroxybutyl)guanine
[no description available]		1.9710
9-(4-hydroxy-2-(hydroxymethyl)butyl)guanine
9-(4-hydroxy-2-(hydroxymethyl)butyl)guanine: structure given in first source		1.9710
cytallene
cytallene: structure given in first source; inhibits replication and cytopathic effect of HIV in vitro		7.6730
ConditionIndicatedRelationship StrengthStudiesTrials
Leukemia L 1210
[description not available]		02.3820
Innate Inflammatory Response
[description not available]		02.0510
Inflammation
A pathological process characterized by injury or destruction of tissues caused by a variety of cytologic and chemical reactions. It is usually manifested by typical signs of pain, heat, redness, swelling, and loss of function.		02.0510
HIV
Human immunodeficiency virus. A non-taxonomic and historical term referring to any of two species, specifically HIV-1 and/or HIV-2. Prior to 1986, this was called human T-lymphotropic virus type III/lymphadenopathy-associated virus (HTLV-III/LAV). From 1986-1990, it was an official species called HIV. Since 1991, HIV was no longer considered an official species name; the two species were designated HIV-1 and HIV-2.		02.3820